Analysts' Mixed Views on ATEC, AMGN, and VRTX: What's the Outlook?

Analysts have been weighing in on several healthcare stocks recently, including Alphatec Holdings (ATEC), Amgen (AMGN), and Vertex Pharmaceuticals (VRTX).

A Needham analyst, David Saxon, maintained a Buy rating on Alphatec Holdings with a price target of $14.00. This is higher than the current share price of $10.35.

The consensus among analysts for Alphatec Holdings is a Strong Buy, with an average price target of $16.42, indicating a potential upside of 64.9% from current levels.

On the other hand, Wells Fargo analyst Mohit Bansal maintained a Hold rating on Amgen with a price target of $400.00, which is lower than the current share price of $390.02.

The consensus among analysts for Amgen is a Moderate Buy, with an average price target of $369.00, representing a -3.1% downside from current levels.

Goldman Sachs analyst Salveen Richter assigned a Buy rating to Vertex Pharmaceuticals with a price target of $653.00, which is higher than the current share price of $478.71.